Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon

Posted on
by

Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon
The Community-Acquired Bacterial Pneumonia Market Forecast report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the 7MM.

DelveInsight’s “Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia Market Forecast

 

Some of the key facts of the Community-Acquired Bacterial Pneumonia Market Report: 

  • The Community-Acquired Bacterial Pneumonia market size was valued USD 2,616 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In April 2024, The US Food and Drug Administration (FDA) has granted approval to Basilea Pharmaceutica’s Zevtera (ceftobiprole medocaril sodium for injection), an antibiotic designed to address various infections. Zevtera is authorized for use in adults with staphylococcus aureus bloodstream infections (SAB) and acute bacterial skin and skin structure infections (ABSSSI). Additionally, it is indicated for the treatment of community-acquired bacterial pneumonia (CABP) in both adult and pediatric patients aged three months and older.
  • CAP continues to be a major source of morbidity and mortality in the US, affecting 649 to 847 persons per 100,000 people and leading to over 1.6 million hospital admissions annually. More than 5 million new cases of CAP are diagnosed each year in the United States; 80% of these cases receive outpatient care with a death rate of less than 1%, and 20% receive inpatient care with a mortality rate of 12% to 40% (Sattar & Sharma, 2021)
  • Males had a greater incidence of CAP than females did (15.56; 95% CI, 13.90e17.43) versus 9.11 (7.87e10.55) per 10,000 people; p 0.0001. Males had greater incidence rates than females did (p 0.0001), and they rose with age
  • DelveInsight calculated that there were 6,886,685 incident cases of community-acquired bacterial pneumonia (CABP) in the 7MM people
  • Germany had the most Community-Acquired Bacterial Pneumonia (CABP) incident instances among the EU5 nations, with 568,953 cases in 2019
  • Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
  • The Community-Acquired Bacterial Pneumonia epidemiology based on gender analyzed that Male ratio is more compare to Female ratio in the case of Community-Acquired Bacterial Pneumonia (CABP)
  • The Community-Acquired Bacterial Pneumonia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Community-Acquired Bacterial Pneumonia pipeline products will significantly revolutionize the Community-Acquired Bacterial Pneumonia market dynamics.

 

Community-Acquired Bacterial Pneumonia Overview

Community-Acquired Bacterial Pneumonia (CABP) is a type of pneumonia that occurs when bacteria infect the lungs and cause inflammation in individuals who have not recently been hospitalized or resided in long-term care facilities. It is one of the most common types of pneumonia and can be caused by various bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, and others.

 

Get a Free sample for the Community-Acquired Bacterial Pneumonia Market Report 

https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market

 

Community-Acquired Bacterial Pneumonia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation:

The Community-Acquired Bacterial Pneumonia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Community-Acquired Bacterial Pneumonia
  • Prevalent Cases of Community-Acquired Bacterial Pneumonia by severity
  • Gender-specific Prevalence of Community-Acquired Bacterial Pneumonia
  • Diagnosed Cases of Episodic and Chronic Community-Acquired Bacterial Pneumonia

 

Download the report to understand which factors are driving Community-Acquired Bacterial Pneumonia epidemiology trends @ Community-Acquired Bacterial Pneumonia Epidemiology Forecast

 

Community-Acquired Bacterial Pneumonia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to get launched during the study period. The analysis covers Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Community-Acquired Bacterial Pneumonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Community-Acquired Bacterial Pneumonia Therapies and Key Companies

  • Omadacycline: Paratek Pharmaceuticals
  • Ceftaroline: Forest Laboratories
  • Delafloxacin: Melinta Therapeutics, Inc.
  • Faropenem: Chia Tai Tianqing Pharma
  • lefamulin: Nabriva Therapeutics
  • Omadacycline: Paratek Pharma
  • BT086: Biotest
  • Nafithromycin: ACM
  • Ceftaroline fosamil: AstraZeneca
  • tigecycline: Pfizer
  • CAL02: Eagle Pharma
  • daptomycin: Cubist Pharma
  • Levofloxacin: Johnson & Johnson

 

Discover more about therapies set to grab major Community-Acquired Bacterial Pneumonia market share @ Community-Acquired Bacterial Pneumonia Treatment Market

 

Scope of the Community-Acquired Bacterial Pneumonia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
  • Community-Acquired Bacterial Pneumonia Therapeutic Assessment: Community-Acquired Bacterial Pneumonia current marketed and Community-Acquired Bacterial Pneumonia emerging therapies
  • Community-Acquired Bacterial Pneumonia Market Dynamics: Community-Acquired Bacterial Pneumonia market drivers and Community-Acquired Bacterial Pneumonia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Community-Acquired Bacterial Pneumonia Unmet Needs, KOL’s views, Analyst’s views, Community-Acquired Bacterial Pneumonia Market Access and Reimbursement 

 

To know more about Community-Acquired Bacterial Pneumonia companies working in the treatment market, visit @ Community-Acquired Bacterial Pneumonia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Community-Acquired Bacterial Pneumonia Market Report Introduction

2. Executive Summary for Community-Acquired Bacterial Pneumonia

3. SWOT analysis of Community-Acquired Bacterial Pneumonia

4. Community-Acquired Bacterial Pneumonia Patient Share (%) Overview at a Glance

5. Community-Acquired Bacterial Pneumonia Market Overview at a Glance

6. Community-Acquired Bacterial Pneumonia Disease Background and Overview

7. Community-Acquired Bacterial Pneumonia Epidemiology and Patient Population

8. Country-Specific Patient Population of Community-Acquired Bacterial Pneumonia 

9. Community-Acquired Bacterial Pneumonia Current Treatment and Medical Practices

10. Community-Acquired Bacterial Pneumonia Unmet Needs

11. Community-Acquired Bacterial Pneumonia Emerging Therapies

12. Community-Acquired Bacterial Pneumonia Market Outlook

13. Country-Wise Community-Acquired Bacterial Pneumonia Market Analysis (2019–2032)

14. Community-Acquired Bacterial Pneumonia Market Access and Reimbursement of Therapies

15. Community-Acquired Bacterial Pneumonia Market Drivers

16. Community-Acquired Bacterial Pneumonia Market Barriers

17.  Community-Acquired Bacterial Pneumonia Appendix

18. Community-Acquired Bacterial Pneumonia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/